Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pituitary ACTH Hypersecretion 2Ovarian Neoplasms 2Hypertension 2Fallopian Tube Neoplasms 2Diabetes Mellitus, Type 2 2Cushing Syndrome 2Adrenocortical Carcinoma 2Adrenal Cortex Neoplasms 2ACTH Syndrome, Ectopic 2Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Adenocarcinoma 1

Interventions

durvalumab 5Nivolumab 3Cyclophosphamide 3Cisplatin 3130-nm albumin-bound paclitaxel 3padeliporfin 2anlotinib 2Trabectedin 2Sunitinib 2Pemetrexed 2Docetaxel 2Chemoradiotherapy 2Carboplatin 2Bevacizumab 2sotorasib 1relatlimab 1relacorilant 1pembrolizumab 1patritumab 1palbociclib 1olaparib 1niraparib 1nintedanib 1montanide ISA 51 1golotimod 1genexol-PM 1ceralasertib 1cemiplimab 1camrelizumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms by Site × relacorilant × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡